THE GLOBAL FUND

List Of Pharmaceutical Products (Hepatitis)
classified according to the Global Fund Quality Assurance Policy

Edition: Version 29 - 30-September-2026 for Hepatitis

The list is an overview of pharmaceutical products subject to the Global Fund Quality Assurance Policy that are listed in National and/or WHO standard treatment guidelines defined in the Global Fund Quality Assurance Policy (Nov 2023). The list is developed as a tool to assist Principal Recipients (PR) of Global Fund grants to identify the status of finished pharmaceutical products according to the Global Fund Quality Assurance Policy.
https://www.theglobalfund.org/media/ojmj2qqn/psm_qa-pharmaceutical-products_policy_en.pdf

Procurement of ERP Reviewed Products: Principal Recipients (PRs) must inform the concerned Fund Portfolio Manager (FPM) at the Global Fund in writing by filling the "Notification Form" (https://www.theglobalfund.org/media/7482/psm_medicinesnotification_form_en.docx) if they intend to procure ERP-reviewed product(s). The Global Fund Secretariat will review the notification request and upon issuing a " no objection" letter to the PR for the requested selection, procurement can only proceed.
For more information on procurement of ERP Reviewed Products: add link for ERP please look at: **https://www.theglobalfund.org/en/sourcing-management/quality-assurance/expert-review-panel/**

Please note that the list is not an exhaustive list. A PR can procure product(s) not listed in the current list as long as PR demonstrates that the product is compliant with the Global Fund Quality Assurance Policy. https://www.theglobalfund.org/media/ojmj2qqn/psm_qa-pharmaceutical-products_policy_en.pdf

YELLOW **s**ignifies a new entry; PINK signifies modification of an existing entry.

For more information, please look at:
https://www.theglobalfund.org/en/sourcing-management/quality-assurance/.

Important Notes

This List may be used by Principal Recipients of Global Fund grants when considering options with respect to procurement of pharmaceutical products pharmaceutical products subject to the Global Fund Quality Assurance Policy. The list aims at providing countries with information that will assist them in their procurement options. Please note that the list is not designed to be a basis for countries to select medicines to be included in their National Treatment Guidelines or to replace any applicable and legally required procurement processes. The Global Fund requires its grant recipients to comply with applicable procurement laws and provides the list only for the **identification of products/manufacturers that comply with the Global Fund's quality assurance policy**. It is important to note that there is no strict requirement to procure according to the list, as long as the Principal Recipients can ensure that the product selected is compliant with the Quality Assurance policy criteria. Furthermore, the Principal Recipient should not rely solely on the information provided in the list but should obtain evidence of products compliance with the Quality Assurance policy. For the above reasons, **we strongly encourage users to ensure they are using the most recent version on our website when conducting procurement.**

The Lists will be updated regularly based on evidence received by the Global Fund. Interested parties are invited to supply information and evidence of products meeting the policy criteria on an ongoing basis. For the above reasons, **we strongly encourage users to ensure they are using the most recent version on our website when conducting procurement.**

Disclaimer:

The Global Fund does not endorse or warrant the fitness of any product on the List for a particular purpose, including in regard of its safety and/or efficacy in the treatment of HIV/AIDS, tuberculosis or malaria. In addition, the Global Fund assumes no responsibility for any misstatement or omission from the list and directs Principal Recipients of Global Fund grants to conduct their own independent confirmation that the information on a given product on the list is accurate before relying on it to make a purchase order for that product, and to ensure that any purchase is in compliance with all the requirements of the Global Fund's quality assurance policy. The Global Fund does not warrant or represent that the products listed have obtained regulatory approval for use of treatment of any disease in any particular country of the world, or that their use is otherwise in accordance with the national laws and regulations of any country, including, but not limited to, intellectual property laws. The Global Fund disclaims any and all liability and responsibility for any injury, death, damage or loss of any kind whatsoever that may arise as a result of, or in connection with the procurement, distribution and use of any product included in the list.

International Non-proprietary name	Strength/ Dose	Dosage form	Supplier/ Manufacturer(s)	WHO Prequalification	SRA	Period Validity for ERP Review	Manufacturing site	Country	Material	Pack
Daclatasvir(dihydrochloride)	30 mg	Tablet	Hetero labs Limited	HP011	NA	NA	Unit 5, Survey No 439, 440, 441 & 458 TSIIC Formulation SEZ, Polepally Village, Jadcherla (M), Mahaboob Nagar District, Telangana, 509 301	India	Blister, Alu-PVC/Aclar ; Bottle, HDPE	10x10's; 28's
Daclatasvir(dihydrochloride)	30 mg	Tablet	Laurus Labs Limited, 2nd Floor, Serene Chambers, Road No. 7, Banjara Hills, Hyderabad, Telangana, 500 034, India	HP027	NA	NA	Laurus Labs Ltd, (Unit-2), Plot No:19, 20 & 21, Western Sector, APSEZ, Atchutapuram Mandal,Visakhapatnam-District, Andhra Pradesh, 531011, India	India	HDPE Bottle	28, 500
Daclatasvir(dihydrochloride)	60 mg	Tablet	Mylan Laboratories Limited	HP016	NA	NA	F- 4 & F-12, MIDC, Malegaon, Sinnar, Nashik - 422 113 Maharashtra	India	HDPE Bottle	28
Daclatasvir(dihydrochloride)	60 mg	Tablet	Hetero labs Limited	HP012	NA	NA	Unit 5, Survey No 439, 440, 441 & 458 TSIIC Formulation SEZ, Polepally Village, Jadcherla (M), Mahaboob Nagar District, Telangana, 509 301	India	HDPE Bottle Blister, Alu-PVC/Aclar	28 10x10's
Daclatasvir(dihydrochloride)	60 mg	Tablet	Laurus Labs Limited, 2nd Floor, Serene Chambers, Road No. 7, Banjara Hills, Hyderabad, Telangana, 500 034, India	HP028	NA	NA	Laurus Labs Ltd, (Unit-2), Plot No:19, 20 & 21, Western Sector, APSEZ, Atchutapuram Mandal,Visakhapatnam-District, Andhra Pradesh, 531011, India	India	Bottle, HDPE	28, 500
Entecavir	0.5 mg	Tablet	Hetero labs Limited	NA	ANDA 205740	NA	Hetero labs Limited, Unit-V, Jadcherla, Mahaboobnagar-509 301, Telangana State	India	HDPE Bottle ; Blister pack	30, 90 ; 10*10's
Entecavir	1.0 mg	Tablet	Hetero labs Limited	NA	ANDA 205740	NA	Hetero labs Limited, Unit-V, Jadcherla, Mahaboobnagar-509 301, Telangana State	India	HDPE Bottle ; Blister pack	30, 90 ; 10*8's
Sofosbuvir/Velpatasvir	400mg+100mg	Tablet, Film-coated	Mylan Laboratories Limited	HP026	NA	NA	F- 4 & F-12, MIDC, Malegaon, Sinnar, Nashik - 422 113 Maharashtra	India	HDPE Bottle	28

International Non-proprietary name	Strength/ Dose	Dosage form	Supplier/ Manufacturer(s)	WHO Prequalification	SRA	Period Validity for ERP Review	Manufacturing site	Country	Material	Pack
Sofosbuvir/Velpatasvir	400mg+100mg	Tablet, Film-coated	Gilead Sciences Ireland UC	HP024	NA	NA	IDA Business & Technology Park, Carrigtohill, County Cork, Ireland Patheon Inc, 2100 Syntex Court, Mississauga, Ontario, L5N 7K9	Canada	Bottle, HDPE	28x1
Sofosbuvir	400 mg	Tablet	Mylan Laboratories Ltd	HP001	NA	NA	F4 & F12 Malegaon MIDC, Sinnar, Nashik District, Maharashtra, 422 113, India	India	HDPE Bottle -White or Blue	28
Sofosbuvir	400 mg	Tablet	Hetero labs Limited	HP002	NA	NA	Hetero labs Limited, Unit-V, Jadcherla, Mahaboobnagar-509 301, Telangana State	India	HDPE Bottle ; Blister pack	14, 28 10x10's
Daclatasvir+Sofosbuvir	60 mg+ 400 mg	Tablet, Film-coated	Mylan Laboratories Limited	HP025	NA	NA	F- 4 & F-12, MIDC, Malegaon, Sinnar, Nashik - 422 113 Maharashtra	India	HDPE Bottle	28